Moderna, Inc.




Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2023-11-30 pm EST Intraday chart for Moderna, Inc. 5-day change 1st Jan Change
77.70 USD -1.66% -0.60% -56.74%
This article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Transcript : Moderna, Inc. Presents at Piper Sandler 35th Annual Healthcare Conference, Nov-30-2023 12:30 PM CI
Generation Bio to Lay Off 40% of Staff in Bid to Extend Cash Runway Into H2 2027 MT
Canaccord Genuity Starts Moderna With Hold Rating, Price Target is $82 MT
Moderna begins work on China mRNA manufacturing site RE
ETF president likes 'battered' Pfizer stock RE
Romanian prosecutors ask to investigate former PM over vaccine contracts RE
Moderna's mRNA Patent Invalidated by European Patent Office MT
European Patent Office declares Moderna mRNA patent invalid RE
Japan to buy 1.4 mln doses of Daiichi Sankyo COVID vaccine RE
Transcript : Moderna, Inc. Presents at 14th Annual Jefferies London Healthcare Conference 2023, Nov-16-2023 08:30 AM CI
Wall Street: a surge in interest rates breaks the bullish rally CF
Transcript : Moderna, Inc. Presents at UBS Biopharma Conference 2023, Nov-09-2023 08:00 AM CI
Moderna Chairman Afeyan on Industry Outlook, Strategy, AI MT
Transcript : Moderna, Inc. - Special Call CI
Arbutus Biopharma Posts Q3 Net Loss, Lower Revenue; CEO to Retire, 24% Research Staff Cut MT
Equity Markets Rise Monday; This Week's Fed Speeches in Focus MT
Equity Markets Edge Higher as Speeches by Fed Officials Loom MT
Moderna, Inc. : melts like snow in the sun
UBS Lowers Moderna's Price Target to $143 From $178, Keeps Buy Rating MT
Dpa-AFX Overview: COMPANIES from 06.11.2023 - 15:15 DP
North American Morning Briefing : Stocks Look to -2- DJ
Health Care Up as Medical Device Makers Shrug Off Drug Competition -- Health Care Roundup DJ
HSBC Upgrades Moderna to Hold From Reduce, Adjusts Price Target to $69 From $89 MT
Goldman Sachs Cuts Price Target on Moderna to $231 From $269, Maintains Buy Rating MT
RBC Cuts Price Target on Moderna to $125 From $180, Keeps Outperform Rating MT
Chart Moderna, Inc.
More charts
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
More Ratings
Mean consensus
Number of Analysts
Last Close Price
Average target price
Spread / Average Target
  1. Stock
  2. Equities
  3. Stock Moderna, Inc. - Nasdaq
  4. News Moderna, Inc.
  5. EU, Moderna Said in Talks for New Supply Deal for COVID-19 Jab
The best tools reserved for subscribers to boost the performance of your investments!
Optimize my profits